Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

III

Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)

ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Colorado, Georgia, Maine, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

IIa

Advanced solid tumors with ALK mutations or high TMB

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Alectinib	ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802	ALK kinase inhibitor
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells

IIa

Recurrent ovarian cancer

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

California, Florida, Louisiana, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Anlotinib	AL3818	VEGFR2/3 kinase inhibitor
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

IIa

Platinum resistant or refractory ovarian cancer with BRCA1/2-mutations

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

California, Colorado, Oregon, South Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986158	BET inhibitor BMS-986158	BET inhibitor
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

IIa

Advanced solid tumors (in expansion)

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Arizona, California, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986205		Inhibits IDO1 to stimulate immune response
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II/III

Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutant ovarian cancer

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Cediranib	Recentin, Cediranib maleate, AZD2171	VEGFR1-3 kinase inhibitor
Liposomal doxorubicin	Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	Topoisomerase II inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor

II

Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations

Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)

Ohio

Drug(s) in Trial	Other Drug Names	Main Known Action
Ponatinib	multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534	Multi-targeted kinase inhibitor

II

Advanced solid tumors with KRAS or NRAS mutations (in expansion)

An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Navitoclax	Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263	Bcl-2, Bcl-XL, and Bcl-w inhibitor
Trametinib	Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212	MEK1/2 inhibitor

II

Advanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterations

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Palbociclib	Ibrance, PD0332991, PD-0332991	CDK4/6 inhibitor

II

Advanced solid tumors with activating HER2 mutations

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.

Arizona, California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Neratinib	HKI-272, PD272	EGFR, HER2, HER4 kinase inhibitor

II

Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Prexasertib	checkpoint kinase 1 inhibitor LY2606368, LY2606368	Chk1/2 inhibitor

II

Platinum resistant or refractory ovarian cancer

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Arizona, Florida, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicin	Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	Topoisomerase II inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor

II

Platinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)

An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

II

Ovarian Expansion for BRCA MUT1/2 or CDKN2A loss or mutation or Advanced solid tumors with molecular alterations in ALK, ROS1, MET, CDK4, CDK6, CSF1R, PDGFR, VEGFR, mTOR, TSC, ERBB2, BRAFV600E/D/K/R, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, ATM, POLD, POLE, high TMB, MSI high)

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Alabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Cetuximab	Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225	EGFR antagonist
Cobimetinib	Cotellic, GDC-0973, XL518	MEK1 inhibitor
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor
Dasatinib	BMS-354825, Sprycel	SRC and bcr-abl kinase inhibitor
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor
Palbociclib	Ibrance, PD0332991, PD-0332991	CDK4/6 inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
Temsirolimus	CCI-779, Torisel	mTOR inhibitor
Trastuzumab	HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin	HER2 antagonist
Vemurafenib	RO5185426, PLX4032, Zelboraf	BRAF kinase inhibitor

II

Advanced solid tumors with alterations in ALK, cKIT, EGFR, ERBB2 AMP, FGFR1-3, FGFR1-3 AMP, GNAQ, GNA11, MET, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, ROS1, SMO, TSC1/2

Molecular Analysis for Therapy Choice (MATCH)

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

Drug(s) in Trial	Other Drug Names	Main Known Action
Afatinib	BIBW 2992 MA2, Gilotrif, Afatinib dimaleate	EGFR, HER2, HER4 kinase inhibitor
Copanlisib	BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor
Erdafitinib	pan-FGFR tyrosine kinase inhibitor JNJ-42756493	pan-FGFR kinase inhibitor
Larotrectinib	Trk inhibitor LOXO-101	Pan-Trk kinase inhibitor
Osimertinib	Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib	EGFR kinase inhibitor
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor
Sapanisertib	TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128	TORC1/2 kinase inhibitor
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
Trametinib	Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212	MEK1/2 inhibitor
Trastuzumab	HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin	HER2 antagonist
Vismodegib	Hedgehog antagonist GDC-0449, Erivedge, GDC-0449	Smoothened antagonist

II

Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101	ALK, TRK, ROS1 kinase inhibitor

II

Advanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53

Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors

Colorado, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Everolimus	Zortress, RAD001, Certican, Afinitor	mTOR inhibitor
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent
Trametinib	Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212	MEK1/2 inhibitor
Veliparib	ABT-888	PARP inhibitor

II

Advanced solid tumors (in ovarian expansion)

A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
PD-0360324	anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324	CSF1R antagonist and tumor-associated macrophage inhibitor
PF-04518600	anti-OX40 antibody PF-04518600	Stimulates OX40 to increase T cell activation and immune response

II

Advanced solid tumors

An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with high MSI

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

California, Colorado, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New Mexico, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

Connecticut, Massachusetts, Ohio, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
AZD6738		ATR kinase inhibitor
Capivasertib	Akt inhibitor AZD5363	pan-AKT inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Recurrent ovarian cancer

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

California, Georgia, New York, Oregon, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
DPX-Survivac	survivin antigen vaccine DPX-Survivac	Immune response against cancer expressing survivin
Epacadostat	3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360	Inhibits IDO1 to stimulate immune response

II

Advanced solid tumors and granulosa cell ovarian cancer (in expansion)

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
methoxyamine	TRC102	Base excision repair inhibitor
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent

II

Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations

A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Prexasertib	checkpoint kinase 1 inhibitor LY2606368, LY2606368	Chk1/2 inhibitor

II

Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)

A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

Arizona, Florida, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
MV-NIS	oncolytic measles virus encoding thyroidal sodium iodide symporter	Induces immune response and tumor cell lysis

II

Advanced NY-ESO-1+ solid tumors

Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL	anti-NY-ESO-1 TCR gene-engineered lymphocytes	Immune response against cancer expressing NY-ESO-1
NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine		Immune response against cancer expressing NY-ESO-1

II

Advanced ovarian germ cell, mucinous, squamous cell, or adenocarcinoma

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Platinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)

Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

California, Maryland, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
Oral Azacitidine	CC-486	DNA methylation inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with lesion treatable with radiotherapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Platinum resistant or refractory ovarian cancer

Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

II

Platinum resistant, refractory or persistent ovarian cancer

A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Connecticut, Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Ixabepilone	Azaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, Ixempra	Microtubule stabilizer/mitotic inhibitor

II

Advanced solid tumors (in expansion)

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

Arizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Azacytidine	azacitidine, Vidaza, Mylosar, 5-AZC	DNA methylation inhibitor
INCB053914	pan-PIM inhibitor INCB053914	PIM1, 2, 3 inhibitor

II

Advanced solid tumors with NTRK1-3 rearrangements

A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Merestinib	c-Met inhibitor LY2801653, LY2801653	Multi-targeted RTK inhibitor

II

Platinum resistant ovarian cancer (<4 prior cytotoxic therapies)

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

California

Drug(s) in Trial	Other Drug Names	Main Known Action
p53MVA	Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53	Immune response against p53 tumor antigen
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with IDH1 or IDH2 mutations

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

California, Connecticut, District of Columbia, Kentucky, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Advanced solid tumors with CCNE1 AMP

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

California, Colorado, Florida, Kentucky, New York, North Carolina, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor

II

Advanced solid tumors

Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency

Florida

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with SETD2 deficiency

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

California, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor

II

Advanced solid tumors (with resectable tumor)

A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Peptide loaded dendritic cell vaccine		Anti-tumor immune response

II

Advanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplifications

A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor

II

Recurrent or persistent endometrioid/clear cell ovarian cancer

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma

Illinois, Rhode Island

Drug(s) in Trial	Other Drug Names	Main Known Action
Tazemetostat	histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438	EZH2 histone methyltransferase inhibitor

II

Recurrent clear cell ovarian cancer

BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Rhode Island

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Platinum resistant or refractory ovarian cancer

Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients

California, Georgia, Illinois, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with MET over-expression or mutation

A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations

California

Drug(s) in Trial	Other Drug Names	Main Known Action
AMG 337		c-Met kinase inhibitor

II

Platinum resistant or refractory ovarian cancer

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer

Alabama, Arizona, Florida, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
DKN-01	DKK1-neutralizing monoclonal antibody DKN-01	Dickkopf-1 (DKK1) antagonist
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

II

Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

New Jersey

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

California, Maryland, New York, Ohio, Oregon, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with CDK12 alterations

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Michigan, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with BRCA1/2 or ATM mutations

A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors

California, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
Talazoparib	Talazoparib Tosylate, BMN-673, MDV3800	PARP inhibitor

II

Recurrent ovarian cancer (PD on or after prior PARP inhibitor)

A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition

Massachusetts, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
MDA-TIL	autologous tumor-infiltrating lymphocytes MDA-TIL	Anti-tumor immune response

II

Recurrent ovarian cancer with high MSI

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

California, Massachusetts, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with high TMB

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

California, Colorado, Florida, Illinois, Indiana, Minnesota, New Jersey, New York, North Carolina, Oregon, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

Ohio

Drug(s) in Trial	Other Drug Names	Main Known Action
Anetumab ravtansine	BAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343	ADC: anti-mesothelin + microtubule destabilizer (DM4)
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

II

Recurrent ovarian cancer

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

California

Drug(s) in Trial	Other Drug Names	Main Known Action
AZD6738		ATR kinase inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Advanced solid tumors with limited progression on checkpoint inhibitor treatment

A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade

New Jersey, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid cancer with ATM truncation mutations or other HR gene mutations

A Phase II Study of M6620 (VX-970) in Selected Solid Tumors

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Berzosertib	VX-970, M6620, VE-822, ATR kinase inhibitor VX-970	ATR kinase inhibitor

II

Low grade serous ovarian cancer

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Oklahoma

Drug(s) in Trial	Other Drug Names	Main Known Action
Letrozole	Femara	Aromatase inhibitor
Ribociclib	Kisqali, LEE011, CDK4/6 Inhibitor LEE011, Kisqali	CDK4/6 inhibitor

II

Advanced solid tumors with POLE and/or POLD1 mutations

A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Platinum resistant or refractory ovarian cancer

A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Arizona, Illinois

Drug(s) in Trial	Other Drug Names	Main Known Action
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor
Relacorilant	CORT125134	GR antagonist

II

Epithelial ovarian cancer (with tumor lesions < 5 cm)

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
DPX-Survivac	survivin antigen vaccine DPX-Survivac	Immune response against cancer expressing survivin
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

California, Colorado, Tennessee, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Lenvatinib	E7080, ER-203492-00, Lenvima	VEGFR1-3 kinase inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with ALK or ROS1 activating genomic aberrations

Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes

Ohio

Drug(s) in Trial	Other Drug Names	Main Known Action
Brigatinib	AP26113	ALK and EGFR kinase inhibitor

II

Advanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusion

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

Arizona, California, Florida, Louisiana, Maryland, Massachusetts, New Jersey, New York, North Carolina, Ohio, Texas, Washington, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Debiopharm 1347	CH5183284, FF284, FGFR Inhibitor Debio 1347	FGFR1-3 inhibitor

II

Advanced solid tumors with prior PD-1/PD-L1 targeted treatment

An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy

California

Drug(s) in Trial	Other Drug Names	Main Known Action
BI 754091	anti-PD-1 monoclonal antibody BI 754091	Blocks PD-L1/2 inhibition of T cells
BI 754111		Blocks LAG-3 inhibition of T cells

Ib/II

Advanced solid tumors

A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

California, Florida, Iowa, Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
AST-008	TLR9 agonist AST-008	TLR agonist and immune cell stimulator
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

Ib/II

Advanced solid tumors with IDH1 mutations

A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Florida, Iowa, Michigan, New Jersey, Texas, Utah

Drug(s) in Trial	Other Drug Names	Main Known Action
FT-2102		mutated IDH1 inhibitor

Ib/II

Advanced solid tumors

An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors

Alabama, New York, Oklahoma, Pennsylvania, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Rebastinib	multitargeted tyrosine kinase inhibitor DCC-2036	Multi-targeted kinase inhibitor

Ib/II

Platinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)

Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)

California, Florida

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
GL-ONC1	light-emitting oncolytic vaccinia virus GL-ONC1	Membrane disrupter
Liposomal doxorubicin	Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	Topoisomerase II inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

Ib/II

Advanced FRalpha+ ovarian cancer

A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Massachusetts, Ohio, Oklahoma, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Mirvetuximab Soravtansine	M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate	ADC: anti-FOLR1 + microtubule destabilizer (DM4)

Ib

Advanced solid tumors

A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
ACY-241	HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241	HDAC inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

Ib

Advanced solid tumors

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Arizona, California, Florida, Iowa, Kansas, Michigan, New York, Pennsylvania, Tennessee, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
ASP8374	PTZ-201	Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

Ib

Advanced solid tumors with high MSI or dMMR

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
L-NMMA	pan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginine	NOS inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

Ib

Advanced solid tumors

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

Arizona, Louisiana, Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
CBP501	G2 checkpoint inhibitor CBP501	G2 checkpoint inhibitor
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

Ib

Advanced solid tumors (inc ovarian expansion)

Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
Trebananib	AMG 386	Angiopoietin 1/2 antagonist

Ib

Recurrent or persistent ovarian cancer

Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin

Florida, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Oregovomab	OvaRex, Monoclonal Antibody B43.13, B43.13	Immune response against cancer expressing CA125
poly ICLC	poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC	Activates dendritic cells and induces interferon production

Ib

Advanced solid tumors

A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors

California, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
NHS-IL12	M9241, immunocytokine NHS-IL12	IL-12 receptor agonist

Ib

Advanced solid tumors

An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.

California, Connecticut, Minnesota, Nevada, North Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor
Xentuzumab	BI-836845	IGF-1/2 antagonist

Ib

Advanced solid tumors

A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
APG-115	MDM2-p53 inhibitor APG-115, p53-HDM2 protein-protein interaction inhibitor APG-115	MDM2 inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

Ib

Recurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2 WT)(inc expansion)

A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Copanlisib	BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor
Niraparib	MK4827, Zejula	PARP inhibitor

Ib

Advanced solid tumors (inc expansion)

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

California, Illinois, North Carolina, Pennsylvania, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Epacadostat	3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360	Inhibits IDO1 to stimulate immune response
INCB050465	PI3K-delta inhibitor INCB050465	PI3K delta inhibitor
MGA012	anti-PD-1 monoclonal antibody MGA012, INCMGA00012	Blocks PD-L1 inhibition of T cells

Ib

Advanced solid tumors (inc expansion)

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors

California, Connecticut, New York, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Camidanlumab Tesirine	anti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301	DNA damaging agent

Ib

Advanced HER2+ solid tumors (inc expansion)

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
PRS-343	anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343	Immune response against cancer expressing HER2

Ib

Platinum resistant or refractory ovarian cancer (inc expansion)

A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy

Illinois, Michigan, Oklahoma, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
Hu5F9-G4	anti-CD47 monoclonal antibody Hu5F9-G4	Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis

Ib

Advanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion)

A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations

Oklahoma, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
ARQ 751	pan-AKT inhibitor ARQ 751	Akt inhibitor
Fulvestrant	Faslodex, ICI 182,780, ZD9238	ER antagonist (SERD)
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

Ib

Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)

Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Irinotecan	Camptosar, Campto, Campothecin-11	Topoisomerase I inhibitor
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

Ib

Advanced solid tumors

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Arizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Niraparib	MK4827, Zejula	PARP inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
TSR-022		Blocks TIM-3 inhibition of T cells
TSR-042	ANB011, anti-PD-1 monoclonal antibody TSR-042	Blocks PD-L1/2 inhibition of T cells

Ib

Advanced solid tumors

A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma

California, Indiana, Missouri, Nevada, New York, North Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
NC-6300	epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912	Topoisomerase II inhibitor

Ib

Advanced solid tumors

A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
CB-839	glutaminase inhibitor CB-839	Glutaminase inhibitor
Talazoparib	Talazoparib Tosylate, BMN-673, MDV3800	PARP inhibitor

Ib

Advanced solid tumors

A Phase 1b Multi-center Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors.

California, Michigan, New Jersey, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
Selumetinib	AZD6244, ARRY-142886	MEK inhibitor

Ia/Ib

Advanced solid tumors (inc expansion)

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors

Connecticut, Florida, New York, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
BI 907828		MDM2 inhibitor

Ia/Ib

Advanced solid tumors (in ovarian expansion)

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

Arizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
FPA150	anti-B7-H4 monoclonal antibody FPA150	blocks B7-H4 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/IIa

Advanced solid tumors

Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors

Arizona, California, Massachusetts, New York, South Dakota

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986277		Undisclosed mechanism
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/IIa

Advanced solid tumors

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

Massachusetts, New Jersey, New York, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986218		Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/IIa

Advanced solid tumors

Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

New Jersey, New York, Pennsylvania, Utah

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986207	anti-TIGIT monoclonal antibody BMS-986207	Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/IIa

Advanced solid tumors

A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors

Maryland, Massachusetts, New York, Pennsylvania, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986179	anti-CD73 monoclonal antibody BMS-986179	Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/IIa

Platinum resistant or refractory mesothelin+ ovarian cancer (inc ovarian expansion)

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy

Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
HPN536	HPN536 - a T cell engaging, mesothelin/CD3-specific TriTAC	directs T cells to kill mesothelin-expressing cancer cells

I/II

Advanced solid tumors

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Connecticut, Florida, New York, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
KY1044		Stimulates ICOS to increase T cell activity and immune response

I/II

Advanced mesothelin+ solid tumors (inc ovarian expansion)

A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor
TC-210 T cells		Immune response against cancer expressing mesothelin

I/II

Platinum resistant or refractory ovarian cancer

Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer

Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
MV-NIS	oncolytic measles virus encoding thyroidal sodium iodide symporter	Induces immune response and tumor cell lysis

I/II

Advanced solid tumors

Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies

California, Colorado, Connecticut, District of Columbia, Illinois, Massachusetts, Missouri, New Jersey, New York, Tennessee, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
JTX-2011	ICOS agonist monoclonal antibody	Stimulates ICOS to increase T cell activity and immune response
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors

Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Cetuximab	Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225	EGFR antagonist
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Monalizumab	IPH2201, anti-NKG2A monoclonal antibody IPH2201	Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytes

I/II

Advanced solid tumors

Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

Arizona, California, Illinois

Drug(s) in Trial	Other Drug Names	Main Known Action
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor
Relacorilant	CORT125134	GR antagonist

I/II

Extrapulmonary small cell ovarian cancer

A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Berzosertib	VX-970, M6620, VE-822, ATR kinase inhibitor VX-970	ATR kinase inhibitor
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor

I/II

Recurrent ovarian cancer

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Cediranib	Recentin, Cediranib maleate, AZD2171	VEGFR1-3 kinase inhibitor
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor

I/II

Platinum resistant ovarian cancer (at least 1 non-platinum therapy)

Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Recurrent, persistent or refractory high grade serous BRCA1/2-mutated ovarian cancer

A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

I/II

Platinum resistant or refractory ovarian cancer (with peritoneal disease)

A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Florida, New York, Ohio, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
ONCOS-102	CGTG-102, Ad5/3-D24-GMCSF, GM-CSF-encoding oncolytic adenovirus CGTG-102	Anti-tumor immune response

I/II

Advanced solid tumors

An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas

California, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Virginia, Washington, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
CX-072		Blocks PD-L1 inhibition of T cells
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Vemurafenib	RO5185426, PLX4032, Zelboraf	BRAF kinase inhibitor

I/II

Recurrent ovarian cancer with Ras pathway alterations or PARP inhibitor resistance

Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor
Selumetinib	AZD6244, ARRY-142886	MEK inhibitor

I/II

Advanced solid tumors

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors

California, Maryland, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Birinapant	Smac Mimetic TL32711, TL32711	SMAC mimetic and IAP antagonist
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Massachusetts, New Jersey, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986226	anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226	Stimulates ICOS to increase T cell activity and immune response
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
LOXO-292	RET kinase inhibitor LOXO-292	RET-kinase inhibitor

I/II

Advanced HER2+ solid tumors

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

Florida, Massachusetts, Michigan, New York, Oklahoma, Oregon, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
A166	anti-HER2 antibody-drug conjugate A166	ADC: anti-HER2 + cytotoxic agent

I/II

Advanced solid tumors

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

California, Connecticut, New Jersey, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
NC318

I/II

Advanced solid tumors

A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors

California, Colorado, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986258	anti-TIM3 antibody BMS-986258	Blocks TIM-3 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid cancers

Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study

Maryland, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
poly ICLC	poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC	Activates dendritic cells and induces interferon production

I/II

Advanced solid tumors

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors

California, Florida, Minnesota, Rhode Island

Drug(s) in Trial	Other Drug Names	Main Known Action
9-ING-41		Downregulates NF-kappaB
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Doxorubicin	14-Hydroxydaunomycin, Hydroxyl-Daunorubicin	Topoisomerase II inhibitor
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
Lomustine	Gleostine, CCNU	DNA damaging agent
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

I/II

Advanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapy

A Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Florida, Oklahoma, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
EDP1503	monoclonal microbial EDP1503
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Recurrent or persistent WT1+ ovarian cancer

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

California, Florida

Drug(s) in Trial	Other Drug Names	Main Known Action
Galinpepimut-S		Immune response against cancer expressing WT1
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

Michigan, North Carolina, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
MGA012	anti-PD-1 monoclonal antibody MGA012, INCMGA00012	Blocks PD-L1 inhibition of T cells
MGC018	A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payload	ADC: anti-B7-H3 + DNA alkylating agent (Duocarmycin)

I/II

Advanced solid tumors

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Colorado, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
BGB-A425		Blocks TIM-3 inhibition of T cells
Tislelizumab	anti-PD-1 monoclonal antibody BGB-A317	Blocks PD-L1/2 inhibition of T cells

I/II

Platinum resistant or refractory ovarian cancer (no prior therapies for resistant/refractory disease)

A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies

California, Massachusetts, New Jersey, New York, Pennsylvania, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Isatuximab	anti-CD38 monoclonal antibody SAR650984	Blocks CD38 and stimulates anti-tumor immune response

I/II

Advanced solid tumor (with at least one injectable tumor)

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

Miami

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
RP1	oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus	Induces immune response and tumor cell lysis

I/II

Advanced solid tumors with activating non-V600 BRAF mutations

A Phase I/II Study of Binimetinib With Encorafenib in Patients With Non-V600 Activating BRAF Mutant Advanced Malignancies

New Jersey, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Binimetinib	ARRY-438162, ARRY-162, MEK inhibitor MEK162, MEK162	MEK inhibitor
Encorafenib	Raf Kinase Inhibitor LGX818, LGX818	RAF inhibitor

I/II

Advanced solid tumors

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients With Solid Tumors

Arizona, Colorado, Connecticut, Florida, Georgia, Iowa, Massachusetts, Michigan, Minnesota, New York, North Carolina, Pennsylvania, Texas, Utah, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
HuMax-AXL-ADC	anti-AXL monoclonal antibody-MMAE conjugate, anti-AXL/MMAE antibody-drug conjugate	ADC: anti-Axl + microtubule destabilizer (MMAE)

I/II

Platinum resistant or refractory ovarian cancer

A Phase 1/2 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer

Massachusetts, New York, Ohio, Oklahoma, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Cemiplimab	anti-PD-1 monoclonal antibody REGN2810, anti-PD-1 monoclonal antibody REGN2810	Blocks PD-L1/2 inhibition of T cells
REGN4018		Immune response against cancer expressing MUC16 (CA125)

I/II

Advanced solid tumors

A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

California, Colorado, Maryland, Missouri, Tennessee, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986205		Inhibits IDO1 to stimulate immune response
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Relatlimab	BMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016	Blocks LAG-3 inhibition of T cells

I/II

Advanced solid tumors with high MSI or dMMR

A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)

Utah

Drug(s) in Trial	Other Drug Names	Main Known Action
Apatinib	YN968D1, Aitan, ATAN, Rivoceranib	c-Met/VEGFR2 kinase inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors

Alabama, California, Georgia, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
INCB001158	CB-1158, Arginase inhibitor	Arginase inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

I/II

Advanced solid tumors (inc expansion)

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)

California, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
CX-2009	anti-CD166 probody-drug conjugate CX-2009, PDC CX-2009, anti-CD166-DM4 CX-2009, ADC CX-2009	ADC: anti-CD166 + microtubule destabilizer (DM4)

I/II

Advanced solid tumors

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Arizona, Connecticut, Florida, Georgia, New York, North Carolina, Oregon, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
NKTR-214		IL-2 receptor agonist
NKTR-262		TLR7/8 agonist and immune cell activator

I/II

Advanced solid tumors

A Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced Cancers

Colorado, Florida, Maryland, Michigan, Nevada, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986253		IL-8 antagonist
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors

California, District of Columbia, Illinois, Michigan, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Tinostamustine	EDO-S101	HDAC inhibitor

I/II

Advanced solid tumors

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Colorado, Florida, Maryland, New Jersey, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986249	Probody of ipilumumab	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
APG-138	SM-138	SMAC mimetic and IAP antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/Ib

Advanced solid tumors (inc expansion)

A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.

Florida, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
NIR178	adenosine A2A receptor antagonist NIR178	Blocks adenosine A2A receptor inhibition of T cells
NZV930	SRF373	Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells
Spartalizumab	anti-PD-1 monoclonal antibody PDR001	Blocks PD-L1/2 inhibition of T cells

I/Ib

Advanced solid ASCT2+ (glutamine transporter) tumors

A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors

North Carolina, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
MEDI7247	antibody-drug conjugate MEDI7247	ADC: anti-ASCT2 + DNA damaging agent (PBD dimers)

I/Ib

Advanced solid tumors (inc expansion--ATR, ATM, CHEK1/2, BRCA1/2, BAP1, BARD1, FANCA/C/D2/E, RAD50/51, PALB2, CDK12, POLE, POLD1, PRKDC, ERCC2, POLQ, MRE11A, NBN mutations or FANCA/C/D2/E or EMSY amplification)

Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes

Illinois

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Veliparib	ABT-888	PARP inhibitor

I/Ib

Advanced solid tumors with MET, AXL, RET, TRK, DDR2, KDR, PDGFRA or KIT alterations (in expansion)

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

California, Colorado, Florida, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Nebraska, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Sitravatinib	MGCD516, multitargeted kinase inhibitor MGCD516	Multi-targeted RTK inhibitor

I/Ib

Advanced solid tumors (inc expansion)

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies

Florida, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
TTX-030	anti-CD39 monoclonal antibody	Inhibits the breakdown of ATP by CD39

I

Advanced solid tumors (inc expansion)

A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

North Carolina, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
AB122		Blocks PD-L1 inhibition of T cells
AB154		Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells

I

Advanced solid tumors (inc expansion)

An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors

Arizona, California, Minnesota, New York, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
MEDI5395		Induces immune response and tumor cell lysis

I

Advanced solid tumors (inc expansion)

A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
IPN60090		Undisclosed mechanism
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I

Advanced solid tumors

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

Alabama, California, Connecticut, North Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
ABBV-368		Stimulates OX40 to increase T cell activation and immune response
ABBV-927	anti-CD40 agonist monoclonal antibody ABBV-927	Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response

I

Advanced solid tumors

A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors

Massachusetts, Texas, Utah, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
TP-3654		PIM1 inhibitor

I

Advanced solid tumors (inc expansion)

An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies

Florida, Tennessee, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
BI 754091	anti-PD-1 monoclonal antibody BI 754091	Blocks PD-L1/2 inhibition of T cells
BI 891065	SMAC mimetic BI 891065	SMAC mimetic and IAP antagonist

I

Advanced solid tumors (in expansion)

A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid Tumors

Arizona

Drug(s) in Trial	Other Drug Names	Main Known Action
TRK-950	monoclonal antibody TRK-950	Undisclosed mechanism

I

Advanced solid tumors

A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Tazemetostat	histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438	EZH2 histone methyltransferase inhibitor

I

Advanced solid tumors

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
ASTX727	CDA inhibitor E7727/decitabine combination agent ASTX727	DNA methylation inhibitor

I

Advanced solid tumors

A Phase 1 Cohort Dose-Escalation Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Advanced or Metastatic Solid Tumor Malignancies

Michigan, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
AVID200		TGFbeta ligand trap

I

Advanced MAGE-A4+, HLA-A1+ solid tumors

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Florida, Missouri, New York, Pennsylvania, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor
MAGE-A4ᶜ¹º³²T	MAGE-A4 SPEAR, engineered T-cells targeting melanoma-associated antigen-A4 (MAGE-A4)	Immune response against cancer expressing MAGE-A4

I

Advanced solid tumors (inc expansion)

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of AO-176

California, Oregon, Tennessee, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
AO-176		Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis

I

Advanced ER+ and HER2+ solid tumors (in expansion)

Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Everolimus	Zortress, RAD001, Certican, Afinitor	mTOR inhibitor
Letrozole	Femara	Aromatase inhibitor
Trastuzumab	HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin	HER2 antagonist

I

Advanced solid tumors

Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer

Vermont

Drug(s) in Trial	Other Drug Names	Main Known Action
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor

I

Advanced solid tumors that are TP53 WT (in expansion)

A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Michigan, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
DS-3032b		MDM2 inhibitor

I

Advanced solid tumors including those with BRCA mutations (in expansion)

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	CDK1, 2, 5, 9 inhibitor
Veliparib	ABT-888	PARP inhibitor

I

Advanced solid tumors

A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Everolimus	Zortress, RAD001, Certican, Afinitor	mTOR inhibitor
Vandetanib	AZD6474, Zactima, ZD6474	VEGFR, EGFR, and RET kinase inhibitor

I

Advanced EphA2+ solid tumors (in expansion)

EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
siRNA-EphA2-DOPC		EphA2 inhibitor

I

Advanced solid tumors

A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors

District of Columbia, Maryland, Massachusetts, Ohio

Drug(s) in Trial	Other Drug Names	Main Known Action
AT13387	Hsp90 inhibitor AT13387	Hsp90 inhibitor
AT7519	CDKI AT7519, cyclin-dependent kinase inhibitor AT7519	CDK1, 2, 4, 6, 9 inhibitor

I

Advanced solid tumors dependent on Wnt ligands (e.g., RNF43 mutations, RSPO fusion); in expansion

A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

California, Maryland, Massachusetts, Michigan, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
LGK974	PORCN inhibitor LGK974, porcupine inhibitor WNT974	WNT ligand secretion inhibitor

I

Advanced solid tumors (in expansion)

A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Cetuximab	Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225	EGFR antagonist
Temsirolimus	CCI-779, Torisel	mTOR inhibitor
Valproic acid	Depacon, Depakene, Stavzor, Valproate	HDAC and NOS inhibitor

I

Advanced solid tumors with FGF/FGFR alterations (in expansion)

Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations

Arizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota, New Mexico, New York, Pennsylvania, South Carolina, Texas, Washington, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
TAS-120	FGFR inhibitor TAS-120	FGFR1-4 inhibitor

I

Advanced solid tumors

A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Dasatinib	BMS-354825, Sprycel	SRC and bcr-abl kinase inhibitor
Temsirolimus	CCI-779, Torisel	mTOR inhibitor

I

Advanced solid tumors (in expansion)

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

California, Connecticut, Florida, Georgia, Missouri, North Carolina, Ohio, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Oleclumab	anti-CD73 monoclonal antibody MEDI9447	Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells